1. Home
  2. SPPL vs KYNB Comparison

SPPL vs KYNB Comparison

Compare SPPL & KYNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SPPL

SIMPPLE LTD.

HOLD

Current Price

$1.94

Market Cap

37.0M

Sector

N/A

ML Signal

HOLD

Logo Kyntra Bio Inc. Common Stock

KYNB

Kyntra Bio Inc. Common Stock

N/A

Current Price

$8.22

Market Cap

32.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SPPL
KYNB
Founded
2016
1993
Country
Singapore
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
37.0M
32.8M
IPO Year
2022
2014

Fundamental Metrics

Financial Performance
Metric
SPPL
KYNB
Price
$1.94
$8.22
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
125.0K
17.7K
Earning Date
04-08-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
9552.08
EPS
N/A
N/A
Revenue
N/A
$6,440,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.50
$6.32
52 Week High
$7.00
$9.58

Technical Indicators

Market Signals
Indicator
SPPL
KYNB
Relative Strength Index (RSI) 32.93 60.53
Support Level $1.58 $6.66
Resistance Level $2.52 $8.99
Average True Range (ATR) 0.20 0.35
MACD 0.00 0.07
Stochastic Oscillator 30.23 73.99

Price Performance

Historical Comparison
SPPL
KYNB

About SPPL SIMPPLE LTD.

Simpple Ltd delivers an ecosystem solution that combines Internet-of-Things devices, robotic solutions, and an integrated software system operating in unison to position buildings to be future-ready. The company operates through two primary segments: the sale, warranty, and maintenance of autonomous robotic cleaning equipment (Robots), and the sale of facilities management software (Facilities management software). The majority of its revenue is generated from the Robots segment. The company has expanded its operations into Australia /New Zealand and may also enter or expand in other geographic markets such as Canada, Hong Kong, Japan, the Middle East, the United Kingdom, Europe and the United States.

About KYNB Kyntra Bio Inc. Common Stock

Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.

Share on Social Networks: